Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Status:
Recruiting
Trial end date:
2028-10-16
Target enrollment:
Participant gender:
Summary
This research is being done to see if it is safe to give investigational combination of study
drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable
(removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching
participants closely for possible side effects from Pembrolizumab and IO102-103. In addition,
participants will be monitored for any delays to their surgery due to the study drugs.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins